Clinical Trial Update: Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating the combination of durvalumab (PD-L1 inhibitor) and olaparib (PARP inhibitor) in patients with advanced cholangiocarcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Imfinzi (durvalumab) (durvalumab)
• Lynparza (Olaparib) (Olaparib)

Snippet

Sponsor: Australasian Gastro-Intestinal Trials Group | Conditions: Cholangiocarcinoma | Phase 2 | Status: RECRUITING